Home
Storia in 1 fonti
Are analysts too quick to gloss over Lilly's liver case?
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
Raccontata da
statnews.com
- ·
Johnson & Johnson advances IBD therapy, despite trial miss
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
- ·
Are analysts too quick to gloss over Lilly's liver case?
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
- ·
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news